Newsroom

News

Every year, the Controlled Release Society (CRS) honors outstanding individuals who have significantly advanced the field of drug delivery. This year, Prof. Claus-Michael Lehr has been awarded the CRS Distinguished Service Award for his long-standing commitment to the society and his influential contributions to pharmaceutical science.

12.06.2025

HIPS

Three intestinal organoids (gray) with spreading Shigella infection (green)

News

Thanks to lab-grown miniature intestines, researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg in collaboration with Uppsala University in Sweden have successfully mapped how aggressive Shigella bacteria infect the human gut. The study, published today in the journal Nature Genetics, opens the door to using cultured human mini-organs to investigate a wide range of other serious infections.

12.06.2025

HIRI

News

New, resistance-breaking drugs are urgently needed to effectively treat infections with antibiotic-resistant germs in the future. Researchers from Saarbrücken and Vienna have now found a possible starting point for the development of such drugs in the natural product Saarvienin A. This novel molecule is capable of killing bacteria even if they are already resistant to clinically used antibiotics. The researchers published their findings in the journal Angewandte Chemie International Edition.

28.05.2025

HIPS

HZI podcast "InFact" with Theresa Graalmann on the topic autoimmune diseases

News

When our immune system chooses the wrong enemy and turns against our own body, autoimmune diseases can result. Dr. Dr. Theresa Graalmann is a physician and clinician scientist who heads the junior research group “Translational Immunology” at TWINCORE – Center for Experimental and Clinical Infection Research. In this episode of the HZI podcast InFact, she explains how rheumatism, lupus, and vascular inflammation develop and how doctors and scientists work together to incorporate patient data and state-of-the-art cell analyses directly into the development of new therapeutic approaches.

27.05.2025

TWINCORE

Study authors Maureen Obara and Dr Matthias Bruhn

News

Monoclonal antibodies against SARS-CoV-2 were considered a promising approach for the prevention and therapy of corona virus infections. However, the ongoing evolution of the virus regularly produces new variants that are no longer neutralized by the antibodies. Researchers from TWINCORE, together with partners from Hanover and Bern, have now been able to clarify the underlying mechanism in more detail. The TWINCORE is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Hannover Medical School (MHH). Instead of using a single antibody, they propose the combination of several antibodies for treatment. They have published their findings in the scientific journal eBioMedicine.

26.05.2025

TWINCORE

News

Decisions have been made on future Clusters of Excellence in the second round of competition under the Excellence Strategy – the joint initiative of the federal and state governments to further strengthen top-level research at universities in Germany. The Helmholtz Centre for Infection Research (HZI) is part of two of the funded Clusters of Excellence together with university partners: RESIST and NUCLEATE. RESIST at Hannover Medical School (MHH) will receive funding for another seven years. In this cluster, scientists are investigating how people who are susceptible to infection can be better protected. In the newly approved NUCLEATE cluster at the Julius-Maximilians-Universität Würzburg (JMU) with the Technical University of Munich and the Ludwig-Maximilians-Universität München, group leaders from the Helmholtz Institute for RNA-based Infection Research (HIRI), a site of the HZI in cooperation with the JMU, are conducting research into nucleic acid-based therapies. A total of 70 Clusters of Excellence were selected for funding.

26.05.2025

HZI Campus

TWINCORE

CiiM

HIRI

Back to the first page
...
9
10
11
12
...
150

HZI in the media

... ein Interview mit Josef Penninger geführt . Er ist wissenschaftlicher Geschäftsführer des Helmholtz-Zentrum für Infektionsforschung in ...

21.12.2025

T3N

Institut für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz-Zentrums für Infektionsforschung (HZI) in ...

19.12.2025

healthcare-in-europe.com

Biosyntheseweg aufzuklären. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in Zusammenarbeit mit ...

18.12.2025

Bionity.COM

Finanzierungsmöglichkeiten fehlen.

Josef Penninger, wissenschaftlicher Geschäftsführer des Helmholtz-Zentrums für Infektionsforschung (HZI)

16.12.2025

MedMedia

Korte from the Technical University of Braunschweig and the Helmholtz Centre for Infection Research (HZI).

The research was carried out as

12.12.2025

The Hindu

... des Leibniz Lungenzentrums Borstel, des Helmholtz-Instituts für Pharmazeutische Forschung Saarland sowie weiterer wissenschaftlicher ...

12.12.2025

Bionity.COM

Einrichtungen des regionalen Forschungsökosystems – darunter das Helmholtz-Zentrum für Infektionsforschung (HZI), das Deutsche Zentrum für

12.12.2025

EUROPE SAYS

Korte of the Technical University of Braunschweig and the Helmholtz Centre for Infection Research (HZI). The findings emerged from the

12.12.2025

The New Indian Express

Universität Würzburg. Seit 2018: Postdoc am Helmholtz-Institut für RNA-basierte Infektionsforschung (HIRI), Entwicklung Bayes’scher ...

12.12.2025

BIOspektrum

Center Borstel - Leibniz Lung Center, the Helmholtz Institute for Pharmaceutical Research Saarland and other scientific institutions in

11.12.2025

Technology Networks

von Humboldt professor, head of department at the Helmholtz Centre for Infection Research, Braunschweig and full professor at the Hannover

10.12.2025

European Research Council

... so Prof. Dr. Berit Lange, Leiterin der Abteilung für Epidemiologie am Helmholtz-Zentrum für Infektionsforschung sowie ...

10.12.2025

Apotheken Umschau

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.